Qualitek Labs Ltd

BSE: 544091

₹ 525-3.36%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 612 crWebsite: www.qualiteklab.comUpdated: 24 Oct 2026

About

Qualitek Labs provides testing, inspection and certification (TIC) services across automotive, defence, electrical and electronics, food and feed, pharmaceuticals and cosmetics, environment and water, mines and minerals, and infrastructure. It reported consolidated revenue of ₹124.5 Cr in FY26, up from ₹70.2 Cr in FY25. As of FY26 it runs a pan-India network of 10 owned labs and 6 PPP labs and has 1200+ employees.^[1][2][3]

Business segments

Transport, Defence & Mechanical made up 40-45% of consolidated revenue in FY26.^[2]
Food & Feed made up 25-30% of consolidated revenue and Pharma 15-20% in FY26.^[2]
The FY26 annual report groups the business into five segments: Transportation & Technology; Food & Lifesciences; Healthcare & Skincare; Natural Resources & Infrastructure; and Environment & Sustainability.^[1]
For reporting purposes, the company has a single segment, testing and inspection services. Revenue from outside India was ₹3.33 Cr in FY26.^[1]

Services and subsidiaries

Transportation testing covers electric vehicles and battery systems, including performance validation, thermal stability and lifecycle assessment (FY26).^[1]
The company also offers technical, managerial and environmental consultancy, occupational safety advisory and laboratory quality management services (FY26).^[1]
Subsidiary Interstellar Testing Centre tests drugs, food, water, chemicals, cosmetics, herbal products and building materials. It also does R&D, including drug discovery and method validation.^[1]
Subsidiary Quality & Testing Infosolution provides software and IT consultancy for the Group's lab and compliance work. Operations run on a Laboratory Information Management System (LIMS).^[1]
LabOps Global Pvt Ltd, an SPV in which the company holds a 74% stake, sets up and operates high-end labs for the private and government sectors.^[1][4]

Lab network and operations

As of FY26 the company had 16 labs (10 owned and 6 PPP), with 290K sq ft of lab space. In FY25 it reported 9 owned labs.^[2][5]
Its sites include Pune Units I & II (automotive, EV battery, defence, electrical and electronics), Noida, Bhubaneswar Units I & II, Paradip (port-based minerals testing), Panchkula, Chennai, Bengaluru and Mumbai.^[1]
The Bengaluru lab is USFDA-approved and tests pharmaceuticals and cosmetics for regulated international markets (FY26).^[1]
The Baddi PPP lab started commercial operations in Jan-25. The company also runs 3 labs for the Gujarat electricity board together with QCI (FY25).^[5]

Key operating numbers

The company ran more than 5 million tests a year in FY26.^[2]
Headcount was 1200+ in FY26, compared with 1000+ in FY25.^[2][5]
Gross margin was 87% in FY26, compared with 85% in FY25.^[2]

Customers and government work

The company had 5000+ customers as of FY25.^[5]
In FY25 it completed government testing programmes for Jal Shakti (1.47 lakh samples) and AMRUT (25,000 samples).^[5]
The Ministry of Coal has empanelled it as one of only 10 third-party agencies for coal testing (FY25).^[5]
In FY25 it received its largest single EMI/EMC testing order, from the defence segment.^[5]
After the end of FY26, the company secured work orders from the Quality Council of India and IOCL.^[1]

Expansion and capex

FY26 capex was ₹51.3 Cr. It covered a food lab acquired in Mumbai, a second lab in Bhubaneshwar, capacity expansion at Panchkula and Chennai, and land and building in Barwala.^[2]
Capex of ₹63 Cr is planned for FY27.^[2]
The acquired USFDA pharma lab was due to be commercial by June 2026, and the Hyderabad food lab acquisition was due to complete by June 2026.^[2]
Planned new revenue streams include an EMI/EMC lab in Pune, an analytical lab in Noida, and accreditation for inspection, certification and fumigation (FY27).^[2]
Plans include expanding Transport/Defence/Mechanical into South India in FY27, expanding Pharma into the West within 2 years, and expanding overseas in FY27.^[2]

Recent developments

On 22 Sep 2026 the company approved a preferential issue of up to 3,86,000 equity shares (up to ₹20,01,60,300) and up to 5,20,000 convertible warrants (up to ₹26,96,46,000).^[6]
Issuance of non-convertible debentures of up to ₹65 crore was approved, as stated in the FY26 annual report.^[1]
The company acquired Interstellar Testing Centre and Quality & Testing Infosolution, which were consolidated from Sep-2024.^[5]

Market Cap

₹612 Cr

High / Low

₹650 / 259

Stock P/E

41.9

Price / Book

7.0

Book Value

₹131

EPS

₹12.5

No. of Shares

1.17 Cr

ROCE

11.9%

ROE

11.9%

OPM

18.5%

Debt / Equity

0.61

Sales

₹125 Cr

Net Profit

₹15 Cr

Promoter holding

56.5%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials